Associations of genomic alteration, tumor mutational burden with PD-L1 expression and response to immune checkpoint inhibitors in Chinese lung patients
机构：[1]First Peoples Hosp Yunnan Prov, Kunming, Yunnan, Peoples R China云南省第一人民医院[2]Guangxi Med Univ, Affiliated Tumor Hosp, Nanning, Peoples R China[3]Shandong Univ, Shandong Acad Med Sci, Shandong Canc Hosp, Jinan, Shandong, Peoples R China[4]Southern Med Univ, Zhujiang Hosp, Guangzhou, Guangdong, Peoples R China南方医科大学珠江医院[5]Fujian Prov Hosp, Fuzhou, Fujian, Peoples R China[6]Guangxi Med Univ, Affiliated Hosp 1, Nanning, Peoples R China[7]Shanxi Med Univ, Hosp 2, Taiyuan, Shanxi, Peoples R China[8]Qingdao Municipal Hosp, Qiandao, Peoples R China[9]OrigiMed Inc, Shanghai, Peoples R China
第一作者机构：[1]First Peoples Hosp Yunnan Prov, Kunming, Yunnan, Peoples R China
推荐引用方式(GB/T 7714)：
Hu Jing,Li Bixun,Zou Bing,et al.Associations of genomic alteration, tumor mutational burden with PD-L1 expression and response to immune checkpoint inhibitors in Chinese lung patients[J].CANCER RESEARCH.2018,78(13):doi:10.1158/1538-7445.AM2018-620.
APA：
Hu, Jing,Li, Bixun,Zou, Bing,Wang, Senming,Qiu, Ye...&Wang, Kai.(2018).Associations of genomic alteration, tumor mutational burden with PD-L1 expression and response to immune checkpoint inhibitors in Chinese lung patients.CANCER RESEARCH,78,(13)
MLA：
Hu, Jing,et al."Associations of genomic alteration, tumor mutational burden with PD-L1 expression and response to immune checkpoint inhibitors in Chinese lung patients".CANCER RESEARCH 78..13(2018)
医学